---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-22-001069"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2022-07-08T23:59:59+00:00"
generated_at: "2026-06-24T18:06:23.647270+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Immunic appoints Maria Törnsén to Board of Directors; Jan Van den Bossche resigns

## Summary
- Appointed Maria Törnsén as Class III director, effective July 5, 2022, term until 2023 annual meeting.
- Granted option to purchase 30,000 shares: 10,000 vesting monthly over 1 year, 20,000 over 3 years.
- Jan Van den Bossche resigned from Board, effective July 5, 2022; no disagreement with company.
- Törnsén brings 20 years commercial experience; current CCO at Passage Bio, previous roles at Sarepta, Sanofi, Shire.

## SEC filing metadata
- accession: 0001193805-22-001069
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2022-07-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380522001069/0001193805-22-001069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380522001069/e621820_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-22-001069
- JSON: https://secwatch.observer/filing/0001193805-22-001069.json
- Plain text: https://secwatch.observer/filing/0001193805-22-001069.txt

## Key facts
- Executive change
  Monika Maria Törnsén was appointed as Director at IMMUNIC, INC..
  - Action: appointed
  - Role: Director
  source text: On July 5, 2022, Immunic, Inc. (the “Company”) announced the appointment of Monika Maria Törnsén as a member of the Board of Directors (the “Board”) of the Company, effective as of July 5, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1280776/000119380522001069/0001193805-22-001069-index.htm
- Executive change
  Jan Van den Bossche resigned as Director at IMMUNIC, INC..
  - Action: resigned
  - Role: Director
  source text: The Company also announced that current Class III director, Jan Van den Bossche, will be resigning from the Board. The Board accepted Mr. Van den Bossche’s resignation effective July 5, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1280776/000119380522001069/0001193805-22-001069-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.